A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

Acta Ophthalmologica

Volumn 97, Issue 1, 2019, Pages 15-23

  Spooner, Kimberly ^a,b,c   Hong, Thomas ^a,b   Bahrami, Bobak ^a,c   Chang, Andrew ^a,b,c  

^a Sydney Retina Clinic & Day Surgery ^*  (Australia)

^b Sydney Retina Clinic   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

aflibercept; anti VEGF; retinal vein occlusion; treatment resistance

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

BEST CORRECTED VISUAL ACUITY; BRANCH RETINA VEIN OCCLUSION; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; DRUG SUBSTITUTION; HUMAN; INJECTION; MACULAR EDEMA; META ANALYSIS; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESISTANT MACULAR EDEMA; ANTAGONISTS AND INHIBITORS; COMPLICATION; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA MACULA LUTEA; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DRUG SUBSTITUTION; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85053726149     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13802     Document Type: Review

References (52)

1. Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480–1487.
2. Bahrami B, Zhu M, Hong T & Chang A (2016): Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 59: 1594–1608.
3. Bahrami B, Hong T, Zhu M, Schlub TE & Chang A (2017): Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255: 1451–1452.
4. Binder S. (2012): Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96: 1–2.
5. Broadhead GK, Hong T & Chang AA (2014): Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. Acta Ophthalmol 92: 713–723.
6. Brown DM, Campochiaro PA, Singh RP et al. (2010): Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1124–1133. e1121
7. Brown DM, Heier JS, Clark WL et al. (2013): Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155: 429–437. e427
8. Campochiaro PA, Sophie R, Pearlman J et al. (2014): Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121: 209–219.
9. Campochiaro PA, Aiello LP & Rosenfeld PJ (2016): Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology 123: S78–S88.
10. Chang AA, Broadhead GK, Hong T et al. (2015): Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res 55: 84–90.
11. Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG & Theodossiadis P. (2017): Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res 58: 203–208.
12. Clark WL, Boyer DS, Heier JS et al. (2016): Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123: 330–336.
13. Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J & Chiang A. (2016): Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 51: 342–347.
14. Coscas G, Loewenstein A, Augustin A et al. (2011): Management of retinal vein occlusion–consensus document. Ophthalmologica 226: 4–28.
15. Downs SH & Black N (1998): The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52: 377–384.
16. Eadie JA, Ip MS & Kulkarni AD (2014): Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina 34: 2439–2443.
17. Egger M & Smith GD (1995): Misleading meta-analysis. BMJ 311: 753–754.
18. Forooghian F, Cukras C, Meyerle CB, Chew EY & Wong WT (2009): Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29: 723–731.
19. Heier JS, Clark WL, Boyer DS et al. (2014): Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121: 1414–1420.e1411.
20. Higgins JP & Thompson SG (2002): Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
21. Higgins JP, Thompson SG, Deeks JJ & Altman DG (2003): Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
22. Jaulim A, Ahmed B, Khanam T & Chatziralli IP (2013): Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 33: 901–910.
23. Khan M, Wai KM, Silva FQ et al. (2017): Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice. Ophthalmic Surg Lasers Imaging Retina 48: 465–472.
24. Klein R, Klein BE, Moss SE & Meuer SM (2000): The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98: 133–141. discussion 141-133.
25. Konidaris V, Al-Hubeshy Z, Tsaousis KT, Gorgoli K, Banerjee S & Empeslidis T (2017): Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab. Int Ophthalmol 38: 207–213.
26. Korobelnik JF, Holz FG, Roider J et al. (2014): Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121: 202–208.
27. Lazzeri S, Ripandelli G & Sartini MS. (2015): Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis 18: 397–432.
28. Lehmann-Clarke L, Dirani A, Mantel I & Ambresin A (2015): The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd 232: 552–555.
29. Meyer CH, Krohne TU & Holz FG (2011): Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31: 1877–1884.
30. Miwa Y, Muraoka Y, Osaka R et al. (2017): Ranibizumab for macular edema after branch retinal vein occlusion: one Initial injection versus three monthly injections. Retina 37: 702–709.
31. Mowat FM, Gonzalez F, Luhmann UF et al. (2012): Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy. Am J Pathol 180: 1726–1739.
32. Noma H, Funatsu H, Mimura T, Harino S & Hori S (2009): Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116: 87–93.
33. Noma H, Mimura T, Yasuda K & Shimura M (2014): Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci 55: 3878–3885.
34. Ogura Y, Roider J, Korobelnik JF et al. (2014): Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158: 1032–1038.
35. Papadopoulos N, Martin J, Ruan Q et al. (2012): Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171–185.
36. Papakostas TD, Lim L, van Zyl T et al. (2016): Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond) 30: 79–84.
37. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW & Hartnett ME (2008): Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331–371.
38. Pfau M, Fassnacht-Riederle H, Becker MD, Graf N & Michels S (2015): Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res 54: 150–156.
39. Rogers S., McIntosh R. L., Cheung N. et al. (2010): The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117: 313–319. e311.
40. Scott IU, VanVeldhuisen PC, Ip MS et al. (2017): Effect of Bevacizumab vs Aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 317: 2072.
41. Shah NJ & Shah UN (2011): Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study. Eye (Lond) 25: 239–244.
42. Sophie R, Hafiz G, Scott AW et al. (2013): Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 156: 693–705.
43. Spooner K, Hong T, Wijeyakumar W & Chang AA (2017): Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol 11: 161–177.
44. Sterne JA, Gavaghan D & Egger M (2000): Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53: 1119–1129.
45. Stewart MW, Rosenfeld PJ & Penha FM (2012): Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 3: 2.
46. Tagami M, Sai R, Fukuda M & Azumi A (2017): Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion. Clin Ophthalmol 11: 403–408.
47. Tah V, Orlans HO, Hyer J, Casswell E, Din N, Sri Shanmuganathan V, Ramskold L & Pasu S (2015): Anti-VEGF therapy and the retina: an update. J Ophthalmol 2015: 627674.
48. Varma R, Bressler NM, Suner I, Lee P, Dolan CM, Ward J, Colman S & Rubio RG (2012): Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology 119: 2108–2118.
49. Ventrice P, Leporini C, Aloe JF et al. (2013): Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4(Suppl 1): S38–S42.
50. Wecker T, Ehlken C, Buhler A, Lange C, Agostini H, Bohringer D & Stahl A (2017): Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101: 353–359.
51. Wirth MA, Becker MD, Graf N & Michels S (2016): Aflibercept in branch retinal vein occlusion as second line therapy: clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study. Int J Retina Vitreous 2: 20.
52. Wolfe JD, Shah AR, Yonekawa Y, Al Faran A, Franklin MS, Abbey AM & Capone A Jr. (2016). Receiver operating characteristic curve to predict anti-VEGF resistance in retinal vein occlusions and efficacy of Ozurdex. Eur J Ophthalmol 26: 168–173.